Company intelligence / Profile preview

Cyclonatix

Ownership: Private
Development stage: Other

Overview

Cyclonatix is an emerging biotechnology company focused on the development of novel cyclodextrin-based therapeutics and delivery systems. The company leverages the unique chemical properties of cyclodextrins to enhance the solubility, stability, and bioavailability of poorly soluble drugs, while also exploring their intrinsic therapeutic potential in lipid-storage disorders. Their primary research focus includes Niemann-Pick disease type C and neurodegenerative conditions like Alzheimer's disease. By engineering specific cyclodextrin derivatives, Cyclonatix aims to overcome the blood-brain barrier and improve targeted delivery to the central nervous system.

Therapeutic areas: CardiovascularNeurologyRare Diseases
Modalities: Small moleculePeptides
Industry: Biotech

Beyond the preview

Go deeper on Cyclonatix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cyclonatix.

Explore the full profile